Antifungal Activities of Natural and Synthetic Iron Chelators Alone and in Combination with Azole and Polyene Antibiotics against Aspergillus fumigatus
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
Antifungal effects of iron chelators (lactoferrin, deferoxamine, deferiprone, and ciclopirox) were tested alone and in combination with antifungal drugs against Aspergillus fumigatus B5233 conidia. Lactoferrin, ciclopirox, and deferiprone inhibited whereas deferoxamine enhanced fungal growth. Antifungal synergy against conidia was observed for combinations of ketoconazole with ciclopirox or deferiprone, lactoferrin with amphotericin B, and fluconazole with deferiprone. Iron chelation alone or combined with antifungal drugs may be useful for prevention and treatment of mycosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“how synergistic a combination is does depend on the exact speciation of the liganded iron”
In the citing paper
“the iron chelator deferasirox promoted the antibacterial activity of ciprofloxacin against V. vulnificus (Neupane and Kim 2010), as did deferiprone with various azoles against Aspergillus fumigatus, while deferoxamine was antagonistic to azoles (Zarember et al. 2009)”
Citations
Cites
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307 · cited 1×
“Invasive aspergillosis in neutropenic and immunocompromised patients is a serious therapeutic challenge (2, 4, 7, 16).”
BackgroundPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813 · cited 2×
“Prophylaxis using antifungal drugs has markedly reduced the occurrence of these infections (8, 19, 23, 24); however, mortality for aspergillosis remains high (17).”
BackgroundMethodAspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409 · cited 1×
“Prophylaxis using antifungal drugs has markedly reduced the occurrence of these infections (8, 19, 23, 24); however, mortality for aspergillosis remains high (17).”
BackgroundAspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,345 · cited 1×
“Prophylaxis using antifungal drugs has markedly reduced the occurrence of these infections (8, 19, 23, 24); however, mortality for aspergillosis remains high (17).”
BackgroundWalsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919 · cited 2×
“Prophylaxis using antifungal drugs has markedly reduced the occurrence of these infections (8, 19, 23, 24); however, mortality for aspergillosis remains high (17).”
BackgroundMethodCombination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541 · cited 1×
“Analysis of the combined effects of different drugs is clinically important since synergistic combinations of drugs may be more efficacious and less toxic than single agents (14, 20, 21).”
BackgroundAn Overview of Drug Combination Analysis with Isobolograms
Tallarida, R. J. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104117 · Cited by 505 · cited 1×
“Isobolic analysis (18, 22) was employed to assess departure from Loewe’s additivity.”
MethodItraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease
Gallin, J. I., Alling, D. W., Malech, H. L., Wesley, R., Koziol, D., Marciano, B., Eisenstein, E. M., Turner, M. L., DeCarlo, E. S., Starling, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021931 · Cited by 400 · cited 1×
“Given the abundance of Aspergillus conidia in the environment, prophylactic antifungal therapy is a standard clinical practice for neutropenic patients (8, 24) or patients with chronic granulomatous disease who experience frequent lifethreatening infections ( 10 ).”
BackgroundSelf-citationBoelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340 · cited 1×
“Deferoxamine mesylate (Sigma) promoted A. fumigatus growth, as has been reported for Rhizopus ( 6 , 9).”
BackgroundThe iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308 · cited 1×
“deferiprone (12) and deferasirox (13) protected mice from”
BackgroundBrakhage, A. (2005) · Current Drug Targets · doi:10.2174/138945005774912717 · Cited by 190 · cited 1×
“Invasive aspergillosis in neutropenic and immunocompromised patients is a serious therapeutic challenge (2, 4, 7, 16).”
BackgroundZarember, K. A., Sugui, J. A., Chang, Y. C., Kwon-Chung, K. J., & Gallin, J. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6367 · Cited by 186 · cited 2×
“In vitro demonstration that lactoferrin inhibits the growth Aspergillus fumigatus conidia by iron deprivation (25) and the topical use of the iron chelator ciclopirox for superficial fungal infections (11) suggest that inhibition of fungal iron acquisition may provide an alternative drug target.”
BackgroundMethodSelf-citationFungal infections in primary immunodeficiencies
Antachopoulos, C., Walsh, T. J., & Roilides, E. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-007-0527-7 · Cited by 181 · cited 1×
“Invasive aspergillosis in neutropenic and immunocompromised patients is a serious therapeutic challenge (2, 4, 7, 16).”
BackgroundDeferiprone iron chelation as a novel therapy for experimental mucormycosis
Ibrahim, A. S., Edwards, J. E., Fu, Y., & Spellberg, B. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl350 · Cited by 156 · cited 1×
“deferiprone (12) and deferasirox (13) protected mice from”
BackgroundKontoyiannis, D. P., Chamilos, G., Lewis, R. E., Giralt, S., Cortes, J., Raad, I. I., Manning, J. T., & Han, X. (2007) · Cancer · doi:10.1002/cncr.22909 · Cited by 152 · cited 1×
“Furthermore, transfusional siderosis and iron overload in malignancy and liver and stem cell transplantation are associated with an increased risk of aspergillosis (1, 3, 15).”
BackgroundAltés, A., Remacha, A. F., Sardà, P., Sancho, F. J., Sureda, A. M., Martino, R., Briones, J., Brunet, S., Canals, C., & Sierra, J. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704628 · Cited by 130 · cited 1×
“Furthermore, transfusional siderosis and iron overload in malignancy and liver and stem cell transplantation are associated with an increased risk of aspergillosis (1, 3, 15).”
Backgroundde Locht, M., Boelaert, J. R., & Schneider, Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90314-x · Cited by 124 · cited 3×
“Deferoxamine mesylate (Sigma) promoted A. fumigatus growth, as has been reported for Rhizopus (6, 9).”
BackgroundInfluentialDie Mischarznei: Versuch einer allgemeinen Pharmakologie der Arzneikombinationen
Loewe, S. (1927) · Journal of Molecular Medicine · doi:10.1007/bf01890305 · Cited by 107
Invasive aspergillosis in primary immunodeficiencies
Almyroudis, N. G., Holland, S. M., & Segal, B. H. (2005) · Medical Mycology · doi:10.1080/13693780400025203 · Cited by 93 · cited 1×
“Invasive aspergillosis in neutropenic and immunocompromised patients is a serious therapeutic challenge (2, 4, 7, 16).”
BackgroundAlexander, J., Limaye, A. P., Ko, C. W., Bronner, M. P., & Kowdley, K. V. (2006) · Liver Transplantation · doi:10.1002/lt.20827 · Cited by 85 · cited 1×
“Furthermore, transfusional siderosis and iron overload in malignancy and liver and stem cell transplantation are associated with an increased risk of aspergillosis (1, 3, 15).”
BackgroundCurrent Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M., Cooper, T., Lewis, J. S., & Ostrosky‐Zeichner, L. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 84 · cited 2×
“Prophylaxis using antifungal drugs has markedly reduced the occurrence of these infections (8, 19, 23, 24); however, mortality for aspergillosis remains high (17).”
BackgroundCombination antifungal therapy: a critical review of the evidence
Ostrosky-Zeichner, L. L. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01983.x · Cited by 66 · cited 1×
“Analysis of the combined effects of different drugs is clinically important since synergistic combinations of drugs may be more efficacious and less toxic than single agents (14, 20, 21).”
BackgroundCiclopirox for the treatment of superficial fungal infections: a review
Gupta, A. K., & Skinner, A. R. (2003) · International Journal of Dermatology · doi:10.1046/j.1365-4362.42.s1.2.x · Cited by 61 · cited 1×
“In vitro demonstration that lactoferrin inhibits the growth Aspergillus fumigatus conidia by iron deprivation (25) and the topical use of the iron chelator ciclopirox for superficial fungal infections (11) suggest that inhibition of fungal iron acquisition may provide an alternative drug target.”
BackgroundCombination antifungals: an update
Segal, B. H., & Steinbach, W. J. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.883 · Cited by 27 · cited 1×
“Analysis of the combined effects of different drugs is clinically important since synergistic combinations of drugs may be more efficacious and less toxic than single agents (14, 20, 21).”
BackgroundSmith, K. J., Diwan, H. A., & Skelton, H. G. (2003) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2003.01712.x · Cited by 18
Balajee, S. A., Imhof, A., Gribskov, J. L., & Marr, K. A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh489 · Cited by 17 · cited 1×
“... strain B5233 (provided by June Kwon-Chung, NIAID), conidia (105) were cultured in 90 l RPMI 1640 without phenol red, buffered with 25 mM HEPES (pH 7.2), in the presence of drugs or buffer (final volume, 100 l). After 16 h at 37°C in a humidified 5% CO2 incubator, 100 lo f RPMI with 5 M 5-chloromethylfluorescein di…”
MethodInfluential
Cited by
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…iron; surprisingly, the iron chelator deferasirox promoted the antibacterial activity of ciprofloxacin against V. vulnificus (Neupane and Kim 2010), as did deferiprone with various azoles against Aspergillus fumigatus, while deferoxamine was antagonistic to azoles (Zarember et al. 2009).”
BackgroundIron - a key nexus in the virulence of Aspergillus fumigatus
Haas, H. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00028 · Cited by 217
Antimicrobial peptides: an alternative for innovative medicines?
da Costa, J. P., Cova, M., Ferreira, R., & Vitorino, R. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6375-x · Cited by 206
“Lactoferrin has been demonstrated to exhibit antimicrobial activity against Aspergillus fumigates (Zarember et al. 2009), Klebsiella pneumoniae , Staphylococcus aureus , and Listeria monocytogenes (Bellamy et al. 1992; Murdock et al. 2007), as well as Streptococcus mutans (Huo et al. 2011) and…”
BackgroundLactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections
Drago-Serrano, M., Campos-Rodríguez, R., Carrero, J., & De la Garza, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030501 · Cited by 151
“Very important is the finding that Lf synergizes with antibiotics and drugs, and even with other proteins of the innate immune system such as lysozyme and natural secretory IgA (sIgA) antibodies, potentiating the antimicrobial effect [63] [64] [65] [66] [67] [68] [69] .”
Iron homeostasis—Achilles’ heel of Aspergillus fumigatus?
Schrettl, M., & Haas, H. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.06.002 · Cited by 139
Metadata
- Authors
- Zarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I.
- Affiliations
- National Institutes of Health (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-06
- Volume
- 53
- Issue
- 6
- Pages
- 2654-2656
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2687209
- OpenAlex
- W2136160579
- Cited by
- 78
- References
- 28
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 10 · 2019: 1 · 2018: 2 · 2017: 10 · 2016: 7 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 6
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- NIH Clinical Center
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- iron chelators, Aspergillus fumigatus, antifungal synergy, lactoferrin, deferoxamine, deferiprone, ciclopirox, azole antifungals, polyene antibiotics, ketoconazole, amphotericin B, fluconazole, fungal conidia
- MeSH terms
- Deferiprone, Ciclopirox, Amphotericin B, Antifungal Agents, Aspergillus fumigatus, Drug Combinations, Iron Chelating Agents, Ketoconazole, Microbial Sensitivity Tests, Pyridones, Fluconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.